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Abstract 
Liver X receptors (LXRs) are transcription factors from the nuclear receptor family that 
can be pharmacologically activated by high-affinity agonists. LXR activation exerts a 
combination of metabolic and anti-inflammatory actions that result in the modulation of 
immune responses and in the amelioration of inflammatory disorders. In addition, LXR 
agonists modulate the metabolism of infected cells and limit the infectivity and/or growth 
of several pathogens. This review gives an overview of the recent advances in 
understanding the complexity of the mechanisms through which the LXR pathway 
controls inflammation and host-cell pathogen interaction. 
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Liver X receptors (LXRs), namely, NR1H3 (LXRα) and NR1H2 (LXRβ), are 
transcription factors from the nuclear receptor family (reviewed in [1]). LXRβ is 
ubiquitously expressed, whereas LXRα expression is more predominant in tissues that 
are highly involved in lipid metabolism. Within the immune system, macrophages, 
dendritic cells, and neutrophils express both isoforms, B lymphocytes express mainly 
LXR, and T cell populations have been reported to express either LXR or both isoforms 
[2–6]. LXRs can be activated by endogenous agonists, including specific oxysterols and 
intermediates of cholesterol biosynthesis, and by specific high-affinity agonists that are 
frequently used in vivo to explore the consequences of pharmacological LXR activation.  
LXRs form heterodimers with retinoid X receptors (RXRs) on LXR response elements 
and, once activated by agonists, they positively regulate the expression of target genes. 
Recent studies have proposed three possible modes of action for LXR- and LXR-
mediated transcriptional activation [7]. Two mechanisms are based on the canonical 
induction of target gene expression by RXR-LXR heterodimers in a pharmacologically 
responsive-manner. In the absence of agonistic activation, the target genes are repressed 
by LXR/RXR heterodimers, which may lead to de-repression in the absence of functional 
LXRs [8]. A third mechanism was proposed, by which the expression of a number of 
transcripts depends on the presence of LXRs, but these transcripts are not upregulated 
upon pharmacological LXR activation [7].  
Most of the targets that are positively induced in response to LXR agonists play key roles 
in lipid and glucose metabolism (reviewed in [1]). These include (but are not restricted 
to) several sterol transporters from the ATP binding cassette (ABC) family, e.g., ABCA1 





(SREBP1c) and carbohydrate regulatory element-binding protein with important 
lipogenic roles; the E3 ubiquitin ligase inducible degrader of the low-density lipoprotein 
receptor (IDOL); and several apolipoproteins involved in lipid transport.  
The use of immortalized murine macrophages that express equivalent levels of FLAG-
tagged LXR or LXR in an LXR-deficient background has contributed in defining the 
specific roles of LXR isoforms in gene regulation. In addition to a signature 
simultaneously regulated by both isoforms, LXRα selectively regulates the expression of 
genes linked to the control of apoptosis and leukocyte migration, whereas LXR-specific 
functions are associated with lymphocyte differentiation and selection [7]. 
In addition to its positive effects on gene transcription, LXRs can negatively affect the 
expression of inflammatory mediators through a plethora of mechanisms, which will be 
further revised in the following section. Agonist-bound LXRs undergo conjugation to 
small ubiquitin-related modifier (SUMO), a process known as SUMOylation, which is 
required for some of the repressive actions of these proteins [9]. Moreover, a study in 
astrocytes proposed different SUMOylation pathways for agonist-bound LXR and 
LXR, mediated by separate members of the SUMO E3 ligase family [10]. 
In a complex scenario combining metabolic and anti-inflammatory actions, LXRs are able 
to modulate immune responses. These actions are particularly relevant in the management 
of an infection, as a number of pathogens are able to hijack host metabolic pathways for 
their own benefit. This review integrates the recent conceptual advances in understanding 
the complexity of mechanisms used by the LXR pathway to control inflammation and the 






LXRs as attenuators of inflammatory disorders 
Accumulated evidence indicates the importance of the LXR pathway in the negative 
control of inflammatory conditions. For example, pharmacological activation of LXRs 
reduced the extent of the inflammatory response in murine models of dermatitis [11,12], 
neuroinflammation [13,14], lupus [15], arthritis [16], and atherosclerosis [12], consistent 
with the fact that LXR-deficient mice develop an age-related lupus-like autoimmune 
disease [17]. Furthermore, several polymorphisms affecting the promoter region of the 
gene encoding LXRα were associated with susceptibility to systemic lupus erythematosus 
in a Korean cohort [18]. 
To explain the anti-inflammatory actions of pharmacologically activated LXRs, many 
studies have focused on the capability of high-affinity agonists to repress pro-
inflammatory gene expression in macrophages and other cell types activated by the 
engagement of toll-like receptors (TLRs) or by endogenous inflammatory cytokines 
[9,12,14,19,20]. The LXR pathway impairs the transcriptional activity of nuclear factor 
kappa B (NF-B) [12] and the recruitment of signal transducer and activator of 
transcription (STAT)1 to target gene promoters [10,14]. Putting together the pieces of 
evidence reported by different groups, it is apparent that several mechanisms contribute 
to the antagonizing actions of the LXR pathway on pro-inflammatory signaling (Figure 
1). First, agonist-bound LXRs underwent SUMOylation and exerted transrepression by 
inhibiting the removal of nuclear receptor co-repressor (NCoR) complexes from pro-
inflammatory gene promoters in response to lipopolysaccharide (LPS) [9,21,22]. In 
macrophages, this process involves the interaction of SUMOylated LXRs with the actin-
binding protein CORONIN 2A (CORO2A). This interaction prevented actin recruitment 
to inflammatory gene promoters [21], in line with more recent evidence on the important 





hepatic acute phase response in mice, the anti-inflammatory effects were selectively 
mediated by SUMOylated LXR and its interaction with the corepressor complex subunit 
G protein pathway suppressor 2 (GPS2) [22]. LXR also attenuated inflammatory 
cytokine production in murine mast cells stimulated with LPS or FcRI crosslinking [24]. 
By contrast, both SUMOylated LXR and LXR contributed in inhibiting the 
transcriptional response of murine macrophages and astrocytes to interferon (IFN)- 
through interference with STAT1 [10,14], which supports the notion that the relative 
contribution of each isoform depends on the cell type and the inflammatory trigger.  
Direct repressive actions have also been proposed involving the binding of LXRs to 
specific sites within macrophage inflammatory gene enhancer elements and potential 
chromatin closure, although additional studies are required to better define this 
mechanism. Gene signatures affected by this repressive activity are associated with 
leukocyte cell-cell adhesion and neutrophil chemotaxis, in line with the inhibitory effects 
of LXR agonists on neutrophil infiltration in a model of zymosan-induced peritonitis in 
mice [25].  
Other mechanisms contributing to the repression of inflammation imply the increased 
transcription of LXR targets in macrophages (Figure 1). First, the cholesterol and 
phospholipid transporter ABCA1, whose upregulation results in changes in membrane 
cholesterol homeostasis that are able to disrupt the recruitment of key adaptor molecules 
to lipid rafts, thereby antagonizing TLR signaling [20]. Second, several enzymes involved 
in the synthesis of fatty acids (fatty acid synthase) and in their conversion to derivatives 
with anti-inflammatory properties (predominantly mediated by stearoyl-CoA desaturase-
2 (SCD2) and its products 9Z palmitoleic acid and oleic acid). The induction of these 





transcription factor SREBP1c, depending on the type of agonist mediating LXR 
activation [26]. Third, MER, a receptor tyrosine kinase that recognizes the plasma protein 
growth arrest-specific 6 (GAS6) bound to phosphatidylserine (PtdSer) on the surface of 
apoptotic bodies and contributes to apoptotic cell clearance. The upregulation of MER 
has been proposed as a mechanism coupling the engulfment of apoptotic cells 
(efferocytosis) with the suppression of inflammatory pathways. Indeed, LXR deficiency 
resulted in an aberrant pro-inflammatory response of macrophages to apoptotic cells and 
in the development of autoimmune disease in mice [17]. Fourth, interferon regulatory 
factor (IRF)8, a transcription factor with multiple roles in myeloid cells. Through the 
upregulation of IRF8, the LXR pathway indirectly induced the expression of interleukin 
(IL)-18 binding protein (IL18BP) in the murine and human systems. IL18BP is a potent 
endogenous inhibitor of the pro-inflammatory cytokine IL-18 [27]. In parallel, LXR 
agonists also repressed IL18 transcription and blocked the processing of pro-IL-18 to its 
bioactive form by interfering with pro-caspase 1 expression and activation, indicating that 
the LXR pathway uses a combination of mechanisms to inhibit IL-18 production [27]. In 
addition, increased expression of IRF8 in murine macrophages overexpressing LXR 
resulted in the upregulation of the anti-inflammatory enzyme arginase 1 [28]. 
Aside from the mechanisms described above, LXR agonists also induce the expression of 
apoptosis inhibitory factor secreted by macrophages (AIM)/CD5L [29,30]. In the murine 
system, this effect is mediated specifically by LXR. AIM/CD5L is a soluble 
scavenger receptor that can also act as a pattern-recognition receptor [31]. The 
endogenous production of human AIM/CD5L enhanced the expression of molecules 
involved in the resolution of inflammation, namely, MER and CD163, increased 





the actions of IL-10 [32], which suggests the possibility that AIM might also be involved 
in facilitating the resolution of inflammation in response to LXR agonists. 
In contrast to predominant anti-inflammatory activities of LXR agonists in macrophages, 
both pro- and anti-inflammatory actions have been reported in dendritic cells. In this 
regard, LXR activation downregulated the expression of the actin-bundling protein fascin 
in human myeloid dendritic cells, suppressing T cell stimulation due to inefficient 
immunological synapse formation [33]. However, prolonged NF-B activation was 
detected in a different study, which translated into increased pro-inflammatory and T cell 
stimulatory activities [34]. Moreover, LXR agonism increased the chemotaxis of murine 
dendritic cells to signals generated in inflammatory settings, such as chemokine (C-C 
motif) ligand (CCL)19 and CCL21. This action was mediated through transcriptional 
activation of the ectoenzyme CD38, which is capable of converting nicotinamide adenine 
dinucleotide (NAD) into cyclic adenosine diphosphoribose (cADPR), an important 
second messenger in leukocyte trafficking [6]. These contrasting observations raise the 
question as to whether the effects of the LXR pathway are influenced by additional factors 
involved in dendritic cell maturation, which requires further exploration. 
In addition to the actions in myeloid cells, LXR agonists inhibited the differentiation of 
murine and human helper T (Th)17 cells [35], which are a subset of CD4+ T cells that 
secrete IL-17 and contribute to the pathogeny of inflammatory diseases [36]. An indirect 
mechanisms was proposed, by which LXR-induced SREBP1 negatively interfered with 
the activity of the transcription factor aryl hydrocarbon receptor on the Il17 promoter. 
The differentiation of other CD4+ T cell populations was also inhibited by LXR agonists 
[37], consistent with the anti-proliferative actions of LXR in murine T cells mediated by 





LXR activation induced regulatory T cell (Treg) expansion. Although a molecular 
mechanism was not defined, the oral administration of an LXR agonist in mice increased 
the abundance of gut-associated Treg with high suppressive capacity [38], which may 
provide additional explanation to the protective effects of the LXR pathway against the 
development of autoimmune diseases.  
The interplay between the metabolic actions of LXRs and their role in the modulation of 
adaptive immune responses was further illustrated by the observation that excessive lipid 
accumulation in LXR-deficient antigen presenting cells induced the expression of B cell 
activating factor (BAFF) and a proliferation inducing ligand (APRIL) that support B cell 
survival and differentiation [39]. This scenario triggered the expansion of auto-reactive 
B cells and contributed to the development of autoimmune disease. In addition, despite 
the fact that B cells mostly express the LXR isoform, the activation of LXR repressed 
BAFF production in human B cell lines through interference with NF-κB, STAT1 and 
mothers against decapentaplegic homolog 3 (SMAD3) signaling [40]. 
Beyond the anti-inflammatory actions in immune cells, transcriptional activation by 
LXRs impairs inflammatory responses in the liver in the context of metabolic disease. In 
particular, lysophosphatidylcholine acyltransferase 3 (LPCAT3) is highly induced by 
LXR agonists in hepatic cells, where it drives the incorporation of unsaturated fatty acids 
into phospholipids [41]. The activity of LPCAT3 resulted in reduced membrane lipid 
saturation, thus inhibiting pro-inflammatory c-Src kinase activation, and in decreased 






Impact of metabolic and anti-inflammatory actions of LXRs on host cell–pathogen 
interaction 
Despite contributing to immunopathology, inflammatory responses are crucial for the 
establishment of an effective immune response against infection. Based on the anti-
inflammatory actions of the LXR pathway, one could expect that LXR agonism would 
lead to deficient immune responses against infection. However, as will be discussed in 
this section, several studies have shown otherwise. Notably, a number of pathogens have 
developed mechanisms to hijack the host immune response and establish intracellular 
infection, particularly in phagocytic cells, even under adverse inflammatory conditions. 
Metabolic reprogramming of host cells or adaptation to their metabolic status are indeed 
common strategies used by intracellular pathogens for survival and replication [42]. 
Interestingly, many studies have shown increased expression and/or activity of LXR 
isoforms in leukocytes infected by intracellular pathogens [30,43–46]. Although the 
signaling pathway/s leading to increased LXR expression during infection have not been 
fully characterized, muramyl dipeptide, a ligand of nucleotide-binding oligomerization 
domain-containing protein 2 (NOD2) that is present in many bacteria, was able to induce 
LXR expression in murine macrophages [30]. In addition, type I and II IFNs and IL-36, 
which are produced during the immune response to infection, as well as LPS from Gram-
negative bacteria, upregulated the expression of enzymes that transform free cholesterol 
into endogenous LXR agonists, such as 25-hydroxycholesterol (25-HC) [14,43,47,48]. 
However, the involvement of LXRs in the physiological actions of 25-HC is still unclear 
[49]. Sterile acute inflammation also increased LXR expression and activity through a 
mechanism requiring functional MER signaling [50], in line with the observation that 





By contrast, LXR expression was inhibited in experimental models of sepsis [51,52] 
and the transcriptional control of LXR target genes was compromised in several 
infection/inflammatory settings [14,15,53]. In this regard, TLR3/4 ligands and IFN- 
interfered with the LXR-mediated control of cholesterol metabolism through activation 
of IRF3 and STAT1, respectively [14,53]. Competition for the coactivator p300/CREB-
binding protein (CBP) was proposed as a mechanism for IRF3 and STAT1 to inhibit the 
transcriptional activity of LXRs on specific target genes.  
Such divergent consequences of infection/inflammation on LXR signaling have fueled 
the need to explore the roles of this pathway in host-pathogen interaction (Figure 2). 
Initial studies in mice have defined the general role for LXRs in promoting macrophage 
survival after infection by different bacteria, namely Listeria monocytogenes, Bacillus 
anthraci), Escherichia coli, and Salmonella Typhimurium, which correlated with the 
upregulated expression of the anti-apoptotic molecule AIM/CD5L, a specific target of 
LXR and with the downregulation of pro-apoptotic factors [29,30]. Deficient LXR 
expression, particularly in bone marrow-derived cells, resulted in a higher susceptibility 
to infection by L. monocytogenes, with increased bacterial burden and neutrophilic 
abscesses in the liver and a lower survival rate [30]. In studies comparing the relative 
contribution of LXR isoforms, the lack of expression of LXR was responsible for the 
increased susceptibility to L. monocytogenes. 
Later on, a solid amount of evidence supported the involvement of LXRs in the control 
of the infection by Mycobacterium tuberculosis (M. tuberculosis). In human macrophages 
and in a murine model of mycobacterial infection, LXR agonists reduced the intracellular 
bacterial burden [43–45]. In line with these observations, LXR-deficient mice had higher 
bacterial burdens and increased granulomatous lesions in the lungs and underwent more 





increased susceptibility of LXR-deficient mice was associated with the impaired activities 
of the innate and adaptive immune systems, including the infiltration of neutrophils to the 
lungs and the establishment of local Th1 and Th17 responses. These observations are in 
contrast with the general anti-inflammatory roles of the LXR pathway in non-infectious 
inflammatory diseases described in the previous section. Interestingly, whereas both 
LXR and LXR participated in limiting mycobacterial infection in human macrophages 
in vitro [43], LXR was specifically required to control the course of infection in mice 
[45], mirroring the selective contribution of this isoform in the protection against L. 
monocytogenes [30].  
In addition, LXR agonists increased the production of antimicrobial peptides in M. 
tuberculosis-infected macrophages [43], consistent with the capability of the LXR target 
AIM/CD5L to enhance this mechanism of defense and to contribute to mycobacterial 
clearance [54]. Therefore, it is plausible that activities regulated by AIM/CD5L beyond 
the control of apoptotic cell death also contribute to the protective effects of LXR agonists 
against bacterial infection. On the other hand, in contrast to the pro-survival actions 
described above, LXR agonists promoted apoptosis in human macrophages infected with 
M. tuberculosis, which may represent a mycobactericidal strategy [44]. Although the 
mechanisms leading to increased cell death were not determined, further investigation is 
required to better understand the implications of the LXR-AIM axis in different types of 
infection and how this pathway integrates with the other transcriptional effects of LXR 
agonists.   
In this regard, the upregulation of the LXR targets ABCA1 and ABCG1, which mediate 
intracellular cholesterol efflux, may also represent an important host mechanism for 
inhibiting mycobacterial growth [44]. Indeed, interference with ABCA1 expression 





macrophages [55], probably because mycobacteria have a preference for intracellular 
fatty acids and cholesterol as carbon sources (reviewed in [56]). The obligate intracellular 
bacterium Chlamydia pneumoniae also relies heavily on intracellular cholesterol and uses 
the TIR domain-containing adapter inducing IFN-β (TRIF)-IRF3 signaling pathway to 
promote the conversion of infected macrophages into cholesterol-loaded foam cells [57]. 
Although this study did not evaluate the effects on cholesterol transporters, the results are 
consistent with the capability of IRF3 to inhibit ABCA1 expression [53]. Interestingly, 
LXR activation interfered with IRF3 activity and inhibited foam cell formation during C. 
pneumoniae infection [57]. Therefore, it is possible that LXR agonists use cooperative 
mechanisms based on the induction of ABCA1/G1 and the repressive actions on IRF3 to 
limit the accumulation of cholesterol and control the infection by bacterial species that 
benefit from intracellular lipid storages. 
Accumulated data support that alterations in the membrane cholesterol as a consequence 
of increased ABCA1 expression may also affect other critical steps in the infection cycle 
of several pathogens. Lipid rafts are membrane microdomains enriched in cholesterol and 
glycosphingolipids that concentrate molecules specifically targeted by a number of 
microorganisms for host cell binding, invasion, or dissemination, as well as receptors that 
initiate signaling pathways in host cells in response to environmental stimuli [58]. Indeed, 
a number of pathogens disrupt cellular cholesterol homeostasis either to promote lipid 
raft formation and gain entry into host cells or to hijack host cell signaling pathways that 
facilitate intracellular survival/replication [59]. For example, human immunodeficiency 
virus (HIV)-1, via its protein Nef, diminished cholesterol efflux from macrophages by 
modulating the post-transcriptional expression of ABCA1 and its redistribution, thus 
facilitating viral infectivity [60]. Reciprocally, the activation of the LXR-ABCA1 axis 





human CD4+ T cells [61], on virus production and the fusion activity of the virions [62], 
and on the capability of human dendritic cells to capture HIV-1 and trans-infect T cells 
[63]. Furthermore, pharmacological treatment with an LXR agonist reduced the viral load 
in humanized models of HIV infection in mice [62,64]. The antiviral effects were not 
exclusive for HIV infection, as the control of cholesterol homeostasis by the LXR-
ABCA1 pathway also impacted the capability of hepatitis C virus (HCV) to establish 
virus-host cell fusions and consequently enter the liver cells [65], as well as both the entry 
and replication capacity of Newcastle disease virus (NDV) [66].  
In addition to mechanisms for cholesterol efflux, LXRs control cholesterol uptake 
through the transcriptional upregulation of IDOL, an E3 ubiquitin ligase that triggers the 
ubiquitination and degradation of several members of the low-density lipoprotein receptor 
(LDLR) family [67]. Therefore, the role of IDOL in lowering intracellular cholesterol 
could help, in combination with the activity of ABCA1/G1, reduce the infectivity and/or 
growth of some pathogens. Moreover, HCV associates with lipoproteins and benefits 
from the surface expression of the LDLR to infect hepatocytes (reviewed in [68]). As the 
overexpression of IDOL inhibited the infection of human hepatocytes with HCV [69], it 
is plausible that a reduction in the LDLR levels represents an additional mechanism 
mediating the inhibitory actions of LXR agonists on HCV entry into host cells.  
Most studies exploring the role of synthetic LXR agonists in viral infection have not 
addressed the exact contribution of LXR isoforms. However, the expression of at least 
LXR(in the absence of pharmacological treatment) was required to restrict the 
reactivation of gammaherpesvirus in chronically infected mice [70]. LXR-deficiency 
resulted in viral reactivation in peritoneal cells, but not in splenocytes, despite intact virus-





The recent discovery of the multifunctional protein CD38 as an additional LXR 
transcriptional target provided new insights to the way LXR agonists control bacterial 
infection [6,71]. Indeed, CD38 exerts multiple roles in the regulation of the immune 
response to pathogens [72]. Its expression in cells originating at the bone marrow was 
required for LXR agonists to ameliorate the clinical severity of S. Typhimurium infection 
in mice [71]. These effects were consistent with the reduced internalization of S. 
Typhimurium by macrophages [71] and may be influenced by an enhanced migratory 
potential of dendritic cells [6] upon activation of the LXR-CD38 axis. CD38 displays 
strong NADase activity, being able to modulate cellular NAD+ homeostasis while 
generating calcium-mobilizing second messengers [73]. It also exerts important 
receptorial and accessory functions in immune cells. Interestingly, the effects of LXR 
agonists on bacterial cell internalization were overcome with exogenous supplementation 
of NAD+ [71], highlighting the potential significance of intracellular NAD+ levels in host 
cell-pathogen interaction. Whether the effects in NAD+ metabolism cooperate with other 
LXR-mediated metabolic changes in the control of infection has not been determined. In 
addition, the contribution of the LXR-CD38 axis in controlling the progression of other 
types of infection requires investigation. 
The LXR pathway can also impact the course of infection through mechanisms based on 
transcriptional repression. As an example, LXR agonists repressed the basal transcription 
of HIV-1 in infected macrophages and counteracted HIV-1 replication in response to TLR 
signaling. These effects were mediated by preventing the release of the corepressor NCoR 
and inhibiting the recruitment of NF-кB, AP1 components, and CBP to the proviral DNA 
[74]. Additionally, the repression of pro-inflammatory genes was also proposed as a 





In line with anti-inflammatory effects in the context of endotoxemia [75], LXR agonists 
reduced organ dysfunction and mortality associated with sepsis in rodent models [51,52]. 
The functional expression of silent mating type information regulation 2 homolog (Sirt)-
1 was required for the protective effects of LXR agonists on myocardial function in septic 
mice, which coincided with a reduction in NF-кB activity, oxidative stress, and 
myocardial cell apoptosis, although the mechanism leading to increased Sirt-1 
transcription/activation was not defined [51]. In addition, evidence was provided for a 
selective role of LXRα, but not of LXR, in the protection against liver injury during 
sepsis [52], which contrasts with the role of LXR in ameliorating the hepatic acute 
response [22]. In general, these observations argue that the LXR pathway plays a role in 
limiting exacerbated tissue damage due to infection. However, in a different study, LXR 
agonism increased sepsis-induced mortality in mice due to an impairment of neutrophil 
infiltration to the infection site [5], raising the possibility that the outcome of LXR 
activation in sepsis depends on additional factors, which warrants further investigation.  
In contrast to the predominant protective effects of the LXR pathway on bacterial and 
viral infections, the anti-inflammatory environment potentiated by LXR agonists may be 
a favorable scenario for certain pathogens. In this regard, LXR deficiency conferred 
resistance to the parasite Leishmania chagasi/infantum [76], despite the fact that 
Leishmania spp. are NAD+ auxotrophs and highly sensitive to the host cell membrane 
cholesterol for infection [77]. Resistance to infection was associated with increased 
production of nitric oxide and IL-1 and augmented parasite killing by LXR-deficient 
macrophages [76]. Similarly, LXR agonists enhanced mortality during Klebsiella 
pneumoniae infection in mice, which correlated with the changes in the course of 
infiltration of neutrophils to the infected lungs [78]. The inhibition of chemokine-induced 





Putting together all of the pieces of evidence obtained from the different models of 
infection, the modulation of inflammatory and metabolic responses by LXRs has different 
consequences depending on the pathogen. Therefore, targeting the LXR pathway as a 
strategy against infection must take into account the multiple mechanisms contributing to 
the effects of LXRs in host cell-pathogen interaction.  
 
Conclusions and future perspectives 
Due to the emergence of antimicrobial resistances and the absence of effective vaccines 
for a large number of pathogens, one of the major necessities in public health is the 
development of innovative host-directed therapies (HDTs) against infection. LXRs, by 
virtue of their condition as druggable targets and their multiple roles at the intersection 
between metabolism and inflammation, are promising candidates for HDT. 
As summarized in this review, LXR activation exerts a protective role in many pre-
clinical models of viral and bacterial infection. Different studies have focused on at least 
one molecular mechanism to explain these protective effects, but it is likely that several 
mechanisms cooperate simultaneously to reduce the capacity of infection of pathogens 
and the inflammatory response. As discussed here, some commonalities exist in relation 
to the metabolic resources hijacked by different pathogens. Accumulated evidence points 
toward the LXR pathway as part of the host response to modulate the metabolism of the 
infected cell and limit the infectivity and/or growth of intracellular pathogens, a role that 
can be boosted upon pharmacological LXR activation. In this regard, cholesterol 
metabolism is targeted by LXR agonists in a manner that is beneficial to limiting the 
infection, at least in animal and in vitro studies. Reciprocally, pathogens that are able to 





more favorable environment. In fact, there is significant evidence of the LXR pathway 
itself being modulated at the level of both expression and activity by signals derived from 
pathogen recognition or from cytokines produced at the infection site. 
In addition, excessive tissue damage due to an exacerbated immune response is a common 
feature in infection and in inflammatory disorders. Beyond its role in limiting the extent 
of infection, activated LXRs trigger mechanisms to keep the inflammatory response under 
control and to avoid excessive organ injury in pre-clinical studies.  
Given their role at the intersection of lipid metabolism and immune responses, the effects 
of LXR activation in the context of infection have been studied in depth in macrophages. 
Indeed, despite their relevance in microbial killing and in the recruitment of immune cells 
to the site of infection, macrophages are commonly targeted by intracellular pathogens 
for their replication and dissemination [79]. Therefore, LXRs limit the extent of infection 
and restrict excessive inflammatory responses in a cell type that represents a selective 
niche for intracellular infection and, at the same time, is crucial for the preservation of 
tissue integrity. Despite the importance of LXRs in macrophage biology, this review also 
integrates data showing the beneficial effects of LXR agonists in other host cells that are 
targets of the infection, especially in the context of viral infection.  
A major limitation in the use of LXR agonists is their adverse effects in pre-clinical 
models of disease due to the activation of a lipogenic program [80]. Based on hepatic 
LXRα as the main isoform involved in agonist-induced lipogenesis, attempts have been 
made to develop LXR-specific ligands to circumvent this problem (reviewed in [1]). 
However, this kind of approach would probably have limitations as a HDT against 
infection. Whereas the anti-inflammatory effects of LXR agonists depend on LXR in a 





protective immune responses against several types of infection (Table I). Therefore, the 
development of more sophisticated agonists that are capable of promoting selective LXR 
functions while inhibiting specific targets [81] and/or new routes of administration 
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Figure 1. LXRs inhibit the inflammatory response in macrophages through multiple 
mechanisms. TLR signaling or IFN- stimulation induce inflammatory gene expression. 
Agonist-bound LXRs mediate mechanisms of transrepression, which interfere with the 
release of corepressors or with the activity/recruitment of transcription factors (NF-B, 
STAT1) required for inflammatory gene expression. In addition, LXRs inhibit 
inflammatory responses indirectly through the transcriptional activation of LXR targets 
(in blue) involved in the modulation of metabolic and/or immune responses. The 
cholesterol efflux mediated by ABCA1 results in changes in the lipid composition of the 
membrane, which interferes with TLR signaling. SREBP1c induces the expresion of 
enzymes involved in the generation of lipids with anti-inflammatory properties. MER 
couples efferocytosis with the suppression of the inflammatory response. AIM/CD5L 
enhances the expression of molecules involved in the resolution of inflammation and 
promotes an anti-inflammatory profile. IRF8 induces the expression of IL18BP, which 
binds to secreted IL-18 and inhibits its biological actions. Some elements in this image 
have been downloaded from SMART - Servier Medical ART. Arg1, arginase 1; Casp1, 
caspase 1; Fas, fatty acid synthase; HDL, high-density lipoprotein; IFNR, IFN- 
receptor; Il1b, interleukin 1; Il12b, interleukin 12 subunit b; Il6, interleukin 6; MyD88, 
Myeloid differentiation primary response 88; TRAF6, tumor necrosis factor receptor 
associated factor 6. 
 
Figure 2. LXR activation induces protective mechanisms that limit viral and 
bacterial infection. LXR agonists upregulate the expression of LXR targets (in blue) that 





AIM/CD5L confers resistance to apoptosis and induces the synthesis of antimicrobial 
peptides. CD38 reduces intracellular NAD+ levels and the infection by S. Typhimurium. 
ABCA1 promotes cholesterol efflux. As a consequence, reduced intracellular cholesterol 
limits the growth of mycobacteria and, potentially, of other bacterial strains that depend 
on intracellular cholesterol. In addition, changes in the cholesterol levels within lipid rafts 
may interfere with the entry of several viruses into host cells. IDOL, by virtue of its role 
in controling the turnover of the LDLR, inhibits the capability of HCV to infect host cells. 
LXRs can also affect the intracellular replication of HIV-1 through mechanisms of 
transrepression, which affect corepressor release or transcription factor recruitment to the 
proviral DNA. Ub, ubiquitin. Some elements in this image have been downloaded from 




Figure 1 Click here to access/download;Figure;Figure 1. LXRs and inflammation DEF.tif
Figure 2 Click here to access/download;Figure;Figure 2. LXRs and infection DEF.tif
Table I. Specific contributions of LXR isoforms to the control of inflammation and infection. Ref., reference. TPA, phorbol 12-myristate-
13-acetate. 
Disease / Cellular model Trigger Species LXR isoform Effects Ref. 
Macrophages (in vitro) LPS; IFN- Mouse LXR LXR Repression of inflammatory genes  [12,14] 
Astrocytes (in vitro) IFN- Mouse LXR LXR Repression of inflammatory genes  [10]  
Lupus-like autoimmunity Aging Mouse LXR LXR Protection from autoimmunity [17] 
Hepatic acute phase response (in vivo) LPS Mouse LXR Repression of acute phase response [22] 
Ear inflammation (in vivo) TPA Mouse LXR Inhibition of inflammation [11] 
Mast cells (in vitro) LPS; FcRI 
crosslinking 
Mouse LXR Repression of inflammatory cytokine 
production 
[24] 
T cells (in vivo; in vitro) Aging; mitogens Mouse LXR Inhibition of proliferation [3] 
Antigen presenting cells (in vivo) Cholesterol 
accumulation  
Mouse LXR Limitation of B cell expansion [39] 
B cell lines (in vitro) Basal conditions Human LXR Repression of BAFF production  [40] 
Table I
Macrophages (in vitro) M. tuberculosis Human LXR LXR Limitation of mycobacterial infection [43] 
M. tuberculosis infection in vivo  M. tuberculosis Mouse LXR Increased resistance to infection [45] 
L. monocytogenes infection in vivo L. monocytogenes Mouse LXR Increased resistance to infection [30] 
GHV infection in vivo GHV Mouse LXR Restriction of viral reactivation in 
peritoneal cells 
[70] 
Cecal ligation and puncture (in vivo) Sepsis Mouse LXR Protection against liver injury [52] 
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have generated a table (Table I) that integrates all the data obtained from reports in which 
isoform-specific actions have been explored. 
3- We have now generated two figures. Fig 1 represents mechanisms involved in the control of 
inflammatory responses in macrophages and Fig 2 represents mechanisms involved in limiting 
infection in general. We have also improved the figure legends so that the interpretation is 
easier. But, please, let us know if these graphics are still not informative. 
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